重编程
诱导多能干细胞
生物
细胞分化
细胞生物学
胚胎干细胞
信使核糖核酸
细胞
计算生物学
遗传学
基因
作者
Luigi Warren,Philip D. Manos,Tim Ahfeldt,Yuin-Han Loh,Hu Li,Frank H. Lau,Wataru Ebina,Pankaj Kumar Mandal,Zachary D. Smith,Alexander Meissner,George Q. Daley,Andrew S. Brack,James J. Collins,Chad A. Cowan,Thorsten M. Schlaeger,Derrick J. Rossi
出处
期刊:Cell Stem Cell
[Elsevier]
日期:2010-11-01
卷期号:7 (5): 618-630
被引量:2276
标识
DOI:10.1016/j.stem.2010.08.012
摘要
Clinical application of induced pluripotent stem cells (iPSCs) is limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically useful cell types are lacking. Here we describe a simple, nonintegrating strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate antiviral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem cells (RiPSCs) into terminally differentiated myogenic cells. This technology represents a safe, efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, and regenerative medicine.
科研通智能强力驱动
Strongly Powered by AbleSci AI